Avego的动态

Avego转发了

查看Alentis Therapeutics的组织主页

9,815 位关注者

We are delighted to announce the successful closing of an oversubscribed Series D financing, raising $181.4M to develop a deep pipeline of CLDN1 targeted medicines for solid tumors. The funding was supported by a syndicate of top-tier biotech investors including OrbiMed as lead and Novo Holdings and JEITO as co-leads as well as substantial contributions from Frazier Life Sciences, Longitude Capital, RA Capital Management, and Catalio Capital Management. This financing is a testament to the transformational potential of CLDN1 targeted medicine in oncology, in particular our first-in-class antibody-drug conjugates (#ADCs) ALE.P02 and ALE.P03. We’re excited to start Phase 1/2 clinical trials for both programs in 2025. Read the full press release: https://lnkd.in/eVSGPG5G We extend our deepest gratitude to our investors for their trust and support. Together we are making a difference ???? #AlentisTherapeutics #Biotech #Funding #Healthcare #LifeSciences #ADC #CLDN1 #Claudin

Thomas Baumert

Professor of Medicine and Chair, Founder Alentis Therapeutics, Director Institute for Translational Medicine Inserm

3 个月

Congratulations and very proud as the founder of Alentis !

Karin Crisanto

Head of Innovation Space & Infrastructure, Member of the Management Board at Basel Area Business & Innovation, Switzerland Innovation Park Basel Area

3 个月

Congratulations to Alentis Therapeutics and the entire team on your impressive Series D financing! We are thrilled to have you at Switzerland Innovation Park Basel Area Main Campus and look forward to seeing the impact of CLDN1 targeted medicines for solid tumors. Switzerland Innovation Park Basel Area - a place where you can shape the future

Fleur Waterston

Associate Consultant | Biomed Graduate

3 个月

Huge congrats to the Alentis Therapeutics team on raising $181.4M in Series D! ?? This strong backing from OrbiMed, Novo Holdings, Jeito Capital, and others highlights the promise of your CLDN1-targeting ADCs. Excited to see ALE.P02 and ALE.P03 make waves in the fight against solid tumors, what key milestones are you most excited to achieve in the next 12-18 months? ?? ??

Superb news, Alentis Therapeutics! Huge congratulations to you, Roberto Iacone & team! We're proud that you're our resident at our Main Campus. Keep on shining!

Congratulations to the Alentis team! What a feat! ??

回复

Fantastic news! Congratulations to the entire Alentis team!

Robert Martinez

Senior Director

3 个月

Love this

Sébastien Simoncelli

Social media marketer for life sciences companies │ Copywriter & Ghostwriter │ Let's discuss how I can help you.

3 个月

Congratulations, Alentis Therapeutics team. It's a great achievement.

回复
Lisa Maffei Luther

Founding Partner and Senior Vice President at Advyzom

3 个月

Congratulations! What an amazing accomplishment for the entire Alentis team! Advyzom is so thrilled to continue to support your major regulatory milestones.

查看更多评论

要查看或添加评论,请登录